Showing results (191-200 of 231) with videos related to
Sort By:
Pageof 24
Brain Communications|June 6, 2022
Coupling cognitive and brainstem dysfunction in multiple sclerosis-related chronic neuropathic limb painPeter Foley, Yazhuo Kong, Ramune Dirvanskiene, et al.The Australasian Journal of Dermatology|August 3, 2019
Atopic dermatitis in adults: An Australian management consensusSaxon Smith, Christopher Baker, Kurt Gebauer, et al.The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.Dermatology and Therapy|June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 TrialsChristopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.Pageof 24